Carbenicillin Disodium
FDA-approved product (injectable, injection), marketed as Geopen, Pyopen.
- Registered studies
- 1
- Lab records
- 10
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Penicillins with extended spectrum
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CA03
Repurposing investigation
Carbenicillin Disodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA75.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli5.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 3 of 5 lab records
- E. coli: measured active in 0 of 3 lab records
- K. pneumoniae: measured active in 0 of 2 lab records
Show the 10 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Carbenicillin Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Levamlodipine MaleateExisting use: Cardiovascular disease, Hypertension58.8% AI-predicted activityagainst M. tuberculosis4 registered studies
- LoxapineExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 2 more58.8% AI-predicted activityagainst M. tuberculosis37 registered studies
- Meclizine HydrochlorideExisting use: Allergic disease, Motion sickness, Nausea and 3 more58.8% AI-predicted activityagainst M. tuberculosis11 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more58.8% AI-predicted activityagainst M. tuberculosis19 registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease58.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Emedastine DifumarateExisting use: Allergic conjunctivitis, Eye allergy58.6% AI-predicted activityagainst M. tuberculosis2 registered studies
- Flavoxate HydrochlorideExisting use: Dysuria, Prostatitis, Urethritis and 1 more58.6% AI-predicted activityagainst M. tuberculosis2 registered studies
- MirtazapineExisting use: Depressive disorder, Insomnia, Major depressive disorder58.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PraziquantelExisting use: Helminthiasis, Infection, Opisthorchiasis and 1 more58.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Latanoprostene BunodExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma58.6% AI-predicted activityagainst M. tuberculosis9 registered studies
- IbrutinibExisting use: Cancer, Chronic lymphocytic leukemia, Macroglobulinemia and 3 more58.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Patients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminated